首頁 > 市場調查報告書 > 製藥

消化器

市場調查報告書

商品編碼

1477509

丁型肝炎市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型（急性、慢性）、診斷（血液測試、彈性成像、肝臟活體組織切片、血清學測試等）、地區和競爭細分，2019- 2029F

Hepatitis D Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Acute, Chronic), By Diagnosis (Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Others), By Region and Competition, 2019-2029F

出版日期: 2024年05月06日 | 出版商:

TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年全球丁型肝炎市場估值為11.1 億美元，預計在預測期內穩定成長，到2029 年複合年成長率為5.25%。感染D病毒（HDV）。它被認為是最嚴重的病毒性肝炎之一，常常使乙型肝炎感染過程變得複雜。全球有數百萬人受到影響，全球丁型肝炎市場在滿足患者的醫療需求、推動研發工作以及製定醫療保健政策方面發揮著至關重要的作用。全球丁型肝炎市場涵蓋各個領域，包括診斷、治療和疫苗。丁型肝炎的診斷測試通常涉及血清學檢測，以檢測與丁型肝炎病毒感染相關的特異性抗體或抗原。治療介入措施主要集中在控制症狀、減少肝臟發炎和預防疾病進展。目前，儘管有幾種研究藥物正在開發中，但尚未批准針對丁型肝炎的特定抗病毒治療方法。此外，正在努力開發有效的丁型肝炎疫苗，旨在提供對丁型肝炎病毒感染的長期保護。

市場概況
預測期	2025-2029
2023 年市場規模	11.1億美元
2029 年市場規模	15.1億美元
2024-2029 年複合年成長率	5.25%
成長最快的細分市場	慢性的
最大的市場	北美洲

主要市場促進因素

丁型肝炎盛行率的增加正在推動全球丁型肝炎市場的發展

不斷提高的意識和篩檢計劃正在推動全球丁型肝炎市場

主要市場挑戰

診斷複雜性：

缺乏具體的治療方案

主要市場趨勢

技術進步

細分市場洞察

類型洞察

診斷見解

區域洞察

Global Hepatitis D Market was valued at USD 1.11 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Hepatitis D, also known as delta hepatitis, is a serious liver infection caused by the hepatitis D virus (HDV). It is considered one of the most severe forms of viral hepatitis, often complicating the course of hepatitis B infection. With millions of people affected worldwide, the global hepatitis D market plays a crucial role in addressing the medical needs of patients, driving research and development efforts, and shaping healthcare policies. The global hepatitis D market encompasses various segments, including diagnostics, therapeutics, and vaccines. Diagnostic tests for hepatitis D typically involve serological assays to detect specific antibodies or antigens associated with HDV infection. Therapeutic interventions mainly focus on managing symptoms, reducing liver inflammation, and preventing disease progression. Currently, there are no specific antiviral treatments approved for hepatitis D, although several investigational drugs are under development. Additionally, efforts to develop an effective hepatitis D vaccine are ongoing, aiming to provide long-term protection against HDV infection.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 1.11 Billion
Market Size 2029	USD 1.51 Billion
CAGR 2024-2029	5.25%
Fastest Growing Segment	Chronic
Largest Market	North America

Key Market Drivers

Increasing Prevalence of Hepatitis D is Driving the Global Hepatitis D Market

Hepatitis, a viral infection causing inflammation of the liver, continues to be a significant public health concern worldwide. Among the various forms of hepatitis, hepatitis B and hepatitis D infections are particularly concerning due to their chronic nature and potential for severe liver damage. In recent years, the increasing prevalence of hepatitis B has been a key driver behind the growth of the global hepatitis D market. Hepatitis B virus (HBV) infection remains a major global health problem, with an estimated 292 million people living with chronic HBV infection globally. The virus is highly contagious and can be transmitted through contact with infected blood or bodily fluids. Inadequate vaccination coverage, unsafe injection practices, and lack of awareness contribute to the ongoing transmission of the virus in many parts of the world.

Hepatitis D virus (HDV) is a defective virus that requires the presence of HBV to replicate. Individuals infected with HBV can also become co-infected with HDV, leading to what is known as hepatitis D or delta hepatitis. Hepatitis D infection can occur either simultaneously with acute HBV infection (co-infection) or in individuals with chronic HBV infection (superinfection). HDV infection is associated with more severe liver disease outcomes compared to HBV infection alone, including higher rates of cirrhosis and liver failure.

Growing Awareness and Screening Programs is Driving the Global Hepatitis D Market

In recent years, there has been a concerted effort to raise awareness about hepatitis D among healthcare professionals, policymakers, and the general public. Governments, non-profit organizations, and healthcare agencies have been actively involved in educational campaigns to highlight the risks associated with hepatitis D infection and the importance of screening, vaccination, and treatment.

One of the key drivers behind the growing awareness of hepatitis D is the implementation of screening programs in high-risk populations. These programs target individuals who are at increased risk of hepatitis D infection, such as those living with chronic hepatitis B, injecting drug users, and individuals from endemic regions where hepatitis D prevalence is high.

Through these screening programs, healthcare providers can identify individuals who are co-infected with hepatitis D and hepatitis B, enabling timely intervention and management. Early detection of hepatitis D infection is crucial for preventing disease progression and reducing the risk of complications.

Advancements in diagnostic technologies have also played a significant role in driving the global hepatitis D market. Newer diagnostic tests, including molecular assays and serological tests, offer improved sensitivity and specificity for detecting hepatitis D infection. These tests allow for accurate diagnosis and monitoring of hepatitis D patients, facilitating better treatment outcomes. While there is currently no specific antiviral therapy approved for the treatment of hepatitis D, research efforts are underway to develop targeted therapies that can effectively suppress HDV replication. Several clinical trials are ongoing to evaluate the safety and efficacy of novel antiviral agents and immune modulators for the management of hepatitis D. In addition to antiviral therapy, management of hepatitis D often involves supportive care to address liver-related complications and optimize liver function. Liver transplantation may be considered in severe cases of hepatitis D-related liver failure.

Key Market Challenges

Diagnostic Complexity:

Accurate diagnosis of hepatitis D relies on specialized laboratory tests, including serological assays and molecular techniques. However, the complexity and cost of these diagnostic methods pose significant challenges, particularly in resource-limited settings where access to advanced healthcare infrastructure and trained personnel may be limited. Simplifying diagnostic algorithms and promoting the development of affordable point-of-care tests are essential steps toward improving diagnostic capabilities globally.

Lack of Specific Treatment Options

Unlike hepatitis B or C, there are currently no approved antiviral therapies specifically targeting hepatitis D. Treatment options for hepatitis D are limited and primarily focus on managing symptoms and preventing disease progression. The absence of targeted therapies underscores the urgent need for innovative research and development efforts aimed at identifying novel therapeutic targets and exploring potential treatment modalities.

Key Market Trends

Technological Advancements

Technological advancements have been revolutionizing various sectors of the healthcare industry, and one area where this progress is particularly evident is in the field of Hepatitis D. Hepatitis D, caused by the hepatitis delta virus (HDV), is a serious liver infection that affects millions of people worldwide. With growing awareness and advancements in technology, the global Hepatitis D market is witnessing significant growth. One of the key drivers of growth in the Hepatitis D market is the development of advanced diagnostic tools. Traditionally, diagnosing Hepatitis D has been challenging due to its overlapping symptoms with other forms of hepatitis. However, with the advent of molecular diagnostic techniques such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), healthcare providers can now accurately detect HDV RNA in patient samples. These tools not only enable early diagnosis but also help in monitoring disease progression and treatment efficacy, thereby driving market growth.

Another significant factor contributing to the growth of the Hepatitis D market is the emergence of improved treatment options. Historically, treatment for Hepatitis D has been limited, with interferon-based therapies being the primary option. However, advancements in drug development have led to the introduction of novel therapeutics targeting various stages of the HDV lifecycle. These include entry inhibitors, RNA interference agents, and host-targeting antivirals, offering new hope for patients with Hepatitis D and driving market expansion.

The rise of telemedicine and remote monitoring technologies has also played a crucial role in driving the Hepatitis D market. Telemedicine allows patients to consult with healthcare providers remotely, eliminating geographical barriers and improving access to care, especially in underserved areas. Additionally, remote monitoring technologies enable healthcare providers to remotely track patients' liver function tests, viral load levels, and medication adherence, facilitating timely interventions and improving patient outcomes.

Artificial intelligence (AI) and machine learning (ML) algorithms are increasingly being integrated into Hepatitis D research and clinical practice, further propelling market growth. These technologies enable the analysis of large datasets, such as genomic data and medical imaging scans, to identify patterns, predict disease progression, and personalize treatment plans. AI-powered diagnostic tools can also assist healthcare providers in interpreting test results more accurately and efficiently, leading to improved patient management and outcomes.

Segmental Insights

Type Insights

Based on the category of type, Chronic emerged as the dominant segment in the global market for Hepatitis D in 2023. Chronic hepatitis D poses significant long-term health risks, including liver cirrhosis, liver cancer, and liver failure. As a result, patients with chronic hepatitis D require ongoing medical monitoring and management, leading to a higher demand for healthcare services and treatments.

Compared to other forms of hepatitis, such as hepatitis B and C, treatment options for hepatitis D are limited. Interferon-based therapies have been the mainstay of treatment for chronic hepatitis D, but they are often associated with adverse side effects and limited efficacy. The lack of highly effective and well-tolerated treatments underscores the importance of developing new therapies specifically targeting chronic hepatitis D.

Diagnosis Insights

The Blood Tests segment is projected to experience rapid growth during the forecast period. Blood tests, such as serological assays and nucleic acid tests (NATs), offer high sensitivity and specificity in detecting markers of hepatitis D infection. These tests can accurately identify the presence of HDV antigens and antibodies in blood samples, enabling reliable diagnosis.

Blood tests are relatively non-invasive and can be performed using standard laboratory equipment. Patients can undergo blood testing at healthcare facilities, clinics, or diagnostic laboratories, making it a convenient option for screening and diagnosis.

Many blood tests for hepatitis D diagnosis have received regulatory approvals from health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These approvals validate the accuracy and reliability of blood-based diagnostic assays, instilling confidence among healthcare providers and patients. Ongoing advancements in laboratory technology have led to the development of more sensitive and efficient blood tests for hepatitis D. Innovations such as real-time polymerase chain reaction (PCR) and next-generation sequencing (NGS) have enhanced the detection capabilities of blood-based assays, further solidifying their dominance in the market.

Regional Insights

North America emerged as the dominant region in the global Hepatitis D market in 2023, holding the largest market share in terms of value. North America boasts of advanced healthcare infrastructure, including state-of-the-art medical facilities, research institutions, and pharmaceutical companies. This infrastructure facilitates early diagnosis, treatment, and research in hepatitis D, thereby driving market growth.

Key Market Players

F. Hoffmann-La Roche Ltd

NanoGen Healthcare Pvt. Ltd.

PROBIOMED SA de CV

3SBio Group

Hepion Pharmaceuticals, Inc.

Antios Therapeutics, Inc.

PharmaEssentia Corporation

Replicor

Apotex Corp.

Mylan N.V

Aurobindo Pharma Limited

Gilead Sciences, Inc.

Report Scope:

In this report, the Global Hepatitis D Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatitis D Market, By Type:

Acute Chronic

Hepatitis D Market, By Diagnosis:

Blood Tests Elastography Liver Biopsy Serologic Testing Others

Hepatitis D Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Hepatitis D Market.

Available Customizations:

Global Hepatitis D market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Global Hepatitis D Market Outlook

4.1. Market Size & Forecast
- 4.1.1. By Value
4.2. Market Share & Forecast
- 4.2.1. By Type (Acute, Chronic)
- 4.2.2. By Diagnosis (Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Others)
- 4.2.3. By Region
- 4.2.4. By Company (2023)
4.3. Market Map
- 4.3.1. By Type
- 4.3.2. By Diagnosis
- 4.3.3. By Region

5. Asia Pacific Hepatitis D Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type
- 5.2.2. By Diagnosis
- 5.2.3. By Country
5.3. Asia Pacific: Country Analysis
- 5.3.1. China Hepatitis D Market Outlook
  - 5.3.1.1. Market Size & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share & Forecast
    - 5.3.1.2.1. By Type
    - 5.3.1.2.2. By Diagnosis
- 5.3.2. India Hepatitis D Market Outlook
  - 5.3.2.1. Market Size & Forecast
    - 5.3.2.1.1. By Value
  - 5.3.2.2. Market Share & Forecast
    - 5.3.2.2.1. By Type
    - 5.3.2.2.2. By Diagnosis
- 5.3.3. Australia Hepatitis D Market Outlook
  - 5.3.3.1. Market Size & Forecast
    - 5.3.3.1.1. By Value
  - 5.3.3.2. Market Share & Forecast
    - 5.3.3.2.1. By Type
    - 5.3.3.2.2. By Diagnosis
- 5.3.4. Japan Hepatitis D Market Outlook
  - 5.3.4.1. Market Size & Forecast
    - 5.3.4.1.1. By Value
  - 5.3.4.2. Market Share & Forecast
    - 5.3.4.2.1. By Type
    - 5.3.4.2.2. By Diagnosis
- 5.3.5. South Korea Hepatitis D Market Outlook
  - 5.3.5.1. Market Size & Forecast
    - 5.3.5.1.1. By Value
  - 5.3.5.2. Market Share & Forecast
    - 5.3.5.2.1. By Type
    - 5.3.5.2.2. By Diagnosis

6. Europe Hepatitis D Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Diagnosis
- 6.2.3. By Country
6.3. Europe: Country Analysis
- 6.3.1. France Hepatitis D Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Diagnosis
- 6.3.2. Germany Hepatitis D Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Diagnosis
- 6.3.3. Spain Hepatitis D Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Diagnosis
- 6.3.4. Italy Hepatitis D Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Type
    - 6.3.4.2.2. By Diagnosis
- 6.3.5. United Kingdom Hepatitis D Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Type
    - 6.3.5.2.2. By Diagnosis

7. North America Hepatitis D Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Diagnosis
- 7.2.3. By Country
7.3. North America: Country Analysis
- 7.3.1. United States Hepatitis D Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Diagnosis
- 7.3.2. Mexico Hepatitis D Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Diagnosis
- 7.3.3. Canada Hepatitis D Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Diagnosis

8. South America Hepatitis D Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Diagnosis
- 8.2.3. By Country
8.3. South America: Country Analysis
- 8.3.1. Brazil Hepatitis D Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Diagnosis
- 8.3.2. Argentina Hepatitis D Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Diagnosis
- 8.3.3. Colombia Hepatitis D Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Diagnosis

9. Middle East and Africa Hepatitis D Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Diagnosis
- 9.2.3. By Country
9.3. MEA: Country Analysis
- 9.3.1. South Africa Hepatitis D Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Diagnosis
- 9.3.2. Saudi Arabia Hepatitis D Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Diagnosis
- 9.3.3. UAE Hepatitis D Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Diagnosis

10. Market Dynamics

10.1. Drivers
10.2. Challenges

11. Market Trends & Developments

11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions

12. Global Hepatitis D Market: SWOT Analysis

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product

14. Competitive Landscape

14.1. F. Hoffmann-La Roche Ltd
- 14.1.1. Company Snapshot
- 14.1.2. Product & Services
- 14.1.3. Financials (In case of listed)
- 14.1.4. Recent Developments
- 14.1.5. SWOT Analysis
14.2. NanoGen Healthcare Pvt. Ltd.
14.3. PROBIOMED SA de CV
14.4. 3SBio Group
14.5. Hepion Pharmaceuticals, Inc.
14.6. Antios Therapeutics, Inc.
14.7. PharmaEssentia Corporation
14.8. Replicor
14.9. Apotex Corp.
14.10. Mylan N.V
14.11. Aurobindo Pharma Limited
14.12. Gilead Sciences, Inc.